Kunshi Biological: JT118 injection has obtained the drug clinical trial approval notification.

Announcement from Junshi Biology: The holding subsidiary, Shanghai Junto Bio Medicine Technology Co., Ltd., has received the "Clinical Trial Approval Notice" issued by the National Medical Products Administration for the clinical trial application of JT118 injection. JT118 is a "two-in-one" recombinant protein vaccine composed of smallpox virus antigens A35 and M1 fusion, intended for the prevention of smallpox virus infection.